Douglas S. Bush, MD

Dr. Douglas Bush is an Associate Professor of Pediatrics in the Division of Pediatric Pulmonology in the Jack and Lucy Clark Department of Pediatrics at the Icahn School of Medicine at Mount Sinai and is the Co-Director of the Pediatric Chronic Lung Care Program at Mount Sinai Kravis Children's Hospital.

After completing his undergraduate studies at Union College and obtaining his medical degree from St. George’s University School of Medicine, he went on to complete his pediatric residency and Chief residency at Cohen Children’s Medical Center and his pediatric pulmonology fellowship at Children’s Hospital Colorado, part of the University of Colorado. Dr. Bush has studied the genetic and molecular contributions to developing pulmonary hypertension in children with Down syndrome. In particular, he has studied the effects of genetic over-expression of chromosome 21 specific anti-angiogenic factors and their contribution to abnormal lung vascular and airway development. In his role at Kravis Children's Hospital, he has co-founded the multi-disciplinary NICU-based Chronic Lung Care Program working to enhance the care delivered to infants with chronic respiratory challenges. This program is part of the multi-institutional, multi-national Bronchopulmonary Dysplasia (BPD) Collaborative - whose mission is to better understand this disorder and to improve the quality of care delivered to infants with BPD.

Although Dr. Bush has expertise in all aspects of pediatric pulmonary disease, he has additional and specific interests in pulmonary hypertension, severe/refractory asthma, chronic lung disease, rare and interstitial lung disease, technology dependence (tracheostomy and/or chronic ventilator dependence) and other developmental lung disorders such as bronchopulmonary dysplasia.

Research
Dr. Bush has focused on airway and pulmonary vascular complications in children with Down syndrome. His research has improved our understanding of the genetic contributions from the 21st chromosome towards the development of lung hypoplasia and pulmonary hypertension in the Down syndrome population.  In addition to his work with the Down syndrome population, in his role as Co-director of the Chronic Lung Care (CLC) Program, he maintains the local CLC patient registry with active work emphasizing the clinical implications of pulmonary vascular disease on outcomes in infants with developmental lung disease.